Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Alembic Pharma gets...

    Alembic Pharma gets USFDA nod for Dorzolamide Hydrochloride Ophthalmic Solution

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-14T09:45:02+05:30  |  Updated On 14 Aug 2019 9:45 AM IST
    Alembic Pharma gets USFDA nod for Dorzolamide Hydrochloride Ophthalmic Solution

    The approved Dorzolamide Hydrochloride Ophthalmic Solution is therapeutically equivalent to the reference listed drug Trusopt Ophthalmic Solution, of Merck Sharp & Dohme Corp.


    New Delhi: Drug firm Alembic Pharmaceuticals on August 13 said it has received approval from the US health regulator for Dorzolamide Hydrochloride Ophthalmic Solution. The drug is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.


    The approved product is therapeutically equivalent to the reference listed drug Trusopt Ophthalmic Solution, of Merck Sharp & Dohme Corp.


    Read Also: Alembic Pharma gets tentative USFDA nod for Bimatoprost Ophthalmic Solution

    The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Dorzolamide Hydrochloride Ophthalmic Solution USP, 2 per cent, Alembic Pharmaceuticals said in a BSE filing.


    Quoting IQVIA data, Alembic Pharmaceuticals said Dorzolamide Hydrochloride Ophthalmic Solution USP, 2 percent, has an estimated market size of USD 35 million for twelve months ending December 2018.


    Read Also: Alembic Pharma gets tentative USFDA nod for Dapagliflozin Tablets to improve glycemic control

    AlembicAlembic PharmaBSEDohme corpDorzolamide HydrochlorideDorzolamide Hydrochloride Ophthalmic Solution USPIntraocular pressureIQVIAMerck Sharpocular hypertensionOphthalmic solutionpharmapharma companypharma newspharma news indiaUS Food and Drug AdministratioUSFDAUSFDA nod
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok